Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2024 and provided a business update. "The Mirum team executed ...

Research Progress on Multidisciplinary Intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Liver Cancer ...

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial ...

Multivariate analysis indicated the presence of intra- and extrahepatic recurrence as independent predictive factors for poor prognosis. Risk factors for intrahepatic recurrence were resection ...

Although subgroup analyses should be interpreted with caution, patients with [intrahepatic cholangiocarcinoma] and [gallbladder cancer] appeared to derive greater PFS benefit from bevacizumab than ...

A recent study suggested that metabolic-associated steatohepatitis can be managed by a multifaceted approach that includes diabetes-related lifestyle modifications, weight loss, and pharmacological ...

Cholangiocarcinomas are malignant tumors that derive from cholangiocytes of small intrahepatic bile ducts ... ICC), or of large hilar or extrahepatic bile ducts (extrahepatic cholangiocarcinoma ...

What is progressive familial intrahepatic cholestasis? Progressive familial intrahepatic cholestasis (PFIC) is a disorder that causes progressive liver disease, which typically leads to liver failure.